SUTRO BIOPHARMA, INC. (STRO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 40M 80M 120M Q1 '17: 14.8M Q2 '17: 15.4M Q3 '17: 17.5M Q4 '17: 4M Q1 '18: 5.8M Q2 '18: 5.7M Q3 '18: 7.8M Q4 '18: 19.1M Q4 '18: 19.1M Q1 '19: 8.6M Q2 '19: 10.5M Q3 '19: 12.3M Q4 '19: 11.3M Q1 '20: 7.2M Q2 '20: 9.5M Q3 '20: 17.8M Q4 '20: 8.3M Q1 '21: 14.7M Q2 '21: 28M Q3 '21: 8.5M Q4 '21: 10.7M Q1 '22: 5.9M Q2 '22: 28.1M Q3 '22: 25.1M Q4 '22: 8.6M Q1 '23: 12.7M Q2 '23: 10.4M Q3 '23: 16.9M Q4 '23: 113.7M Q1 '24: 13M Q2 '24: 25.7M Q3 '24: 8.5M Q4 '24: 14.8M Q1 '25: 17.4M Q2 '25: 63.7M Q3 '25: 9.7M Q4 '25: 11.6M Q1 '26: 14.5M Q2 '26: 9.8M Q4 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '17: -1.1M Q4 '17: -15.2M Q1 '18: -11.7M Q2 '18: -12.1M Q3 '18: -10.2M Q4 '18: -3.3M Q1 '19: -14.3M Q2 '19: -13.7M Q3 '19: -12.7M Q4 '19: -14.8M Q1 '20: -19.2M Q2 '20: -16.4M Q3 '20: -10.6M Q4 '20: -24.8M Q1 '21: -19M Q2 '21: -9.8M Q3 '21: -34.7M Q4 '21: -35M Q1 '22: -39.1M Q2 '22: -19.4M Q3 '22: -21.2M Q4 '22: -49.2M Q1 '23: -42.2M Q2 '23: -46.2M Q3 '23: -44M Q4 '23: 43.2M Q1 '24: -56.6M Q2 '24: -48.7M Q3 '24: -67.9M Q4 '24: -65.3M Q1 '25: -68.5M Q2 '25: -3.3M Q3 '25: -48.5M Q4 '25: -38M Q1 '26: -29.7M Q2 '26: -29.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '17: -1.1M Q2 '17: -1.8M Q3 '17: -1.4M Q4 '17: -15.3M Q1 '18: -12M Q2 '18: -11.5M Q3 '18: -10.2M Q4 '18: -1.5M Q4 '18: -1.5M Q1 '19: -14.2M Q2 '19: -13.8M Q3 '19: -12.9M Q4 '19: -14.8M Q1 '20: -19.6M Q2 '20: 29.9M Q3 '20: 17.1M Q4 '20: -59.5M Q1 '21: -30.4M Q2 '21: -6.2M Q3 '21: -30.9M Q4 '21: -38.1M Q1 '22: -39.1M Q2 '22: -26M Q3 '22: -19.5M Q4 '22: -34.6M Q1 '23: -50M Q2 '23: -38.5M Q3 '23: -49.3M Q4 '23: 31.1M Q1 '24: -58.2M Q2 '24: -48M Q3 '24: -48.8M Q4 '24: -72.4M Q1 '25: -76M Q2 '25: -11.5M Q3 '25: -56.9M Q4 '25: -46.8M Q1 '26: -38.5M Q2 '26: -38.5M Q4 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q4 '17: -4.8M Q1 '18: -15M Q2 '18: -13.9M Q3 '18: 47.6M Q4 '18: -5.9M Q1 '19: -20.1M Q2 '19: -15.6M Q3 '19: -16.1M Q4 '19: -13.2M Q1 '20: -18.7M Q2 '20: -12.5M Q3 '20: -17.7M Q4 '20: -18.9M Q1 '21: -30.4M Q2 '21: -5.3M Q3 '21: -24.4M Q4 '21: -21.6M Q1 '22: -35.3M Q2 '22: -3.2M Q3 '22: 65.9M Q4 '22: -23.9M Q1 '23: -61M Q2 '23: -31.2M Q3 '23: -33.5M Q4 '23: 14.1M Q1 '24: -64.7M Q2 '24: 9.5M Q3 '24: -64.5M Q4 '24: -71.7M Q1 '25: -67.9M Q2 '25: -44.7M Q3 '25: -38.2M Q4 '25: -26.4M Q1 '26: -42.3M Q2 '26: -38.3M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q4 '17: -5.5M Q1 '18: -15.4M Q2 '18: -14M Q3 '18: 47.2M Q4 '18: -6.7M Q1 '19: -20.4M Q2 '19: -16.1M Q3 '19: -16.8M Q1 '20: -19.5M Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q1 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '19: 22.9M Q3 '19: 22.9M Q2 '20: 31.8M Q3 '20: 37.9M Q2 '21: 46.1M Q3 '21: 46.2M Q1 '22: 46.5M Q2 '22: 47M Q3 '22: 52.3M Q1 '23: 58.7M Q2 '23: 60.3M Q3 '23: 60.6M Q1 '24: 61.5M Q2 '24: 81.2M Q3 '24: 82M Q1 '25: 8.4M Q2 '25: 8.5M Q3 '25: 84.9M Q1 '26: 13.1M Q2 '26: 16.6M Q3 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q4 '17: -43.27 Q1 '18: -66.47 Q2 '18: -86.57 Q3 '18: -104.69 Q4 '18: -71.25 Q1 '19: -46.12 Q2 '19: -22.55 Q3 '19: -1.85 Q4 '19: -2.43 Q1 '20: -2.65 Q2 '20: -1.11 Q3 '20: -0.10 Q4 '20: -0.93 Q1 '21: -0.75 Q2 '21: -1.82 Q3 '21: -2.94 Q4 '21: -2.29 Q1 '22: -2.47 Q2 '22: -2.89 Q3 '22: -2.59 Q4 '22: -2.37 Q1 '23: -2.38 Q2 '23: -2.47 Q3 '23: -2.91 Q4 '23: -1.78 Q1 '24: -1.52 Q2 '24: -1.47 Q3 '24: -1.25 Q4 '24: -29.10 Q1 '25: -37.59 Q2 '25: -38.35 Q3 '25: -38.43 Q4 '25: -31.88 Q1 '26: -25.74 Q2 '26: -26.72 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.